Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
- PMID: 19501581
- DOI: 10.1016/j.clinbiochem.2009.05.018
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease
Abstract
Background: The metabolic syndrome is a constellation of common metabolic disorders that is associated with cardiovascular disease. Insulin resistance has a central role in the pathophysiology of metabolic syndrome.
Recent advances: It is now commonly accepted that chronic inflammation associated with visceral obesity induces insulin resistance in the liver. Chronic inflammation is characterized by the production of abnormal adipokines and cytokines such as TNF-alpha, FFA, IL-1, IL-6, leptin and resistin. These factors inhibit insulin signalling in hepatocytes by activating SOCS proteins, several kinases such as JNK, IKK-beta and PKC and protein tyrosine phosphatases such as PTP1B and PTEN, that in turn impair insulin signalling at insulin receptor and insulin receptor substrate (IRS) level. Hepatic insulin resistance in turn causes impaired suppression of glucose production by insulin in hepatocytes leading to hyperglycemia. An important and early complication of hepatic insulin resistance is the induction of hepatic VLDL production, via changes in the rate of apoB synthesis and degradation and de novo lipogenesis, or increased FFA flux from adipose tissue into the liver. Insulin resistance also stimulates the production of CRP and PAI-1, both markers of an inflammatory state. All metabolic abnormalities related to hepatic insulin resistance have been shown to directly or indirectly promote atherosclerosis. Hyperglycemia induces a series of alterations including endothelial dysfunction, cellular proliferation, changes in extracellular matrix conformation and impairment of LDL receptor-mediated uptake decreasing the in vivo clearance of LDL. Small dense LDLs associated with high circulating VLDL have higher affinity to the intimal proteoglycans leading to the penetration of more LDL particles into the arterial wall. CRP can also accelerate atherosclerosis by increasing the expression of PAI-1 and adhesion molecules in endothelial cells, inhibition of nitric oxide formation and increasing LDL uptake into macrophages.
Conclusions: Overall, growing evidence suggests that hepatic insulin resistance is sufficient to induce several components of the metabolic syndrome and promote progression to cardiovascular disease. Many unresolved questions remain however on the molecular and cellular mechanisms that trigger hepatic insulin resistance and promote the development of clinical metabolic syndrome.
Similar articles
-
Insulin resistance in obesity as the underlying cause for the metabolic syndrome.Mt Sinai J Med. 2010 Sep-Oct;77(5):511-23. doi: 10.1002/msj.20212. Mt Sinai J Med. 2010. PMID: 20960553 Review.
-
Hemostasis alterations in metabolic syndrome (review).Int J Mol Med. 2006 Nov;18(5):969-74. Int J Mol Med. 2006. PMID: 17016629 Review.
-
Recent advances in the relationship between obesity, inflammation, and insulin resistance.Eur Cytokine Netw. 2006 Mar;17(1):4-12. Eur Cytokine Netw. 2006. PMID: 16613757 Review.
-
Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.Panminerva Med. 2005 Dec;47(4):201-10. Panminerva Med. 2005. PMID: 16489319 Review.
-
The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.Semin Vasc Med. 2002 Feb;2(1):45-57. doi: 10.1055/s-2002-23095. Semin Vasc Med. 2002. PMID: 16222595 Review.
Cited by
-
Iron Overload Induces Hepatic Ferroptosis and Insulin Resistance by Inhibiting the Jak2/stat3/slc7a11 Signaling Pathway.Cell Biochem Biophys. 2024 May 27. doi: 10.1007/s12013-024-01315-8. Online ahead of print. Cell Biochem Biophys. 2024. PMID: 38801513
-
Role of apigenin in targeting metabolic syndrome: A systematic review.Iran J Basic Med Sci. 2024;27(5):524-534. doi: 10.22038/IJBMS.2024.71539.15558. Iran J Basic Med Sci. 2024. PMID: 38629096 Free PMC article. Review.
-
Protein tyrosine phosphatase 1B in metabolic diseases and drug development.Nat Rev Endocrinol. 2024 Jun;20(6):366-378. doi: 10.1038/s41574-024-00965-1. Epub 2024 Mar 22. Nat Rev Endocrinol. 2024. PMID: 38519567 Review.
-
Altered Autonomic Function in Metabolic Syndrome: Interactive Effects of Multiple Components.J Clin Med. 2024 Feb 3;13(3):895. doi: 10.3390/jcm13030895. J Clin Med. 2024. PMID: 38337589 Free PMC article. Review.
-
Exercise-induced effects on asprosin and indices of atherogenicity and insulin resistance in males with metabolic syndrome: a randomized controlled trial.Sci Rep. 2024 Jan 10;14(1):985. doi: 10.1038/s41598-024-51473-1. Sci Rep. 2024. PMID: 38200061 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous